Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Polymer-Ligand-Based ELISA for Robust, High-Throughput, Quantitative Detection of p53 Aggregates.

Maritschnegg E, Heinzl N, Wilson S, Deycmar S, Niebuhr M, Klameth L, Holzer B, Koziel K, Concin N, Zeillinger R.

Anal Chem. 2018 Nov 20;90(22):13273-13279. doi: 10.1021/acs.analchem.8b02373. Epub 2018 Oct 29.

PMID:
30277755
2.

Correction: Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells.

Kramer D, Stark N, Schulz-Heddergott R, Erytch N, Edmunds S, Roßmann L, Bastians H, Concin N, Moll UM, Dobbelstein M.

Cell Death Differ. 2018 Sep 3. doi: 10.1038/s41418-018-0190-8. [Epub ahead of print]

PMID:
30177736
3.

The genetic landscape of 87 ovarian germ cell tumors.

Van Nieuwenhuysen E, Busschaert P, Neven P, Han SN, Moerman P, Liontos M, Papaspirou M, Kupryjanczyk J, Hogdall C, Hogdall E, Oaknin A, Garcia A, Mahner S, Trillsch F, Cibula D, Heitz F, Concin N, Speiser P, Salvesen H, Sehouli J, Lambrechts D, Vergote I.

Gynecol Oncol. 2018 Oct;151(1):61-68. doi: 10.1016/j.ygyno.2018.08.013. Epub 2018 Aug 28.

PMID:
30170975
4.

Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study.

Vergote I, von Moos R, Manso L, Van Nieuwenhuysen E, Concin N, Sessa C.

Gynecol Oncol. 2018 Sep;150(3):471-477. doi: 10.1016/j.ygyno.2018.07.018. Epub 2018 Jul 27.

5.

Morphology and tumour-infiltrating lymphocytes in high-stage, high-grade serous ovarian carcinoma correlated with long-term survival.

Darb-Esfahani S, Kolaschinski I, Trillsch F, Mahner S, Concin N, Vergote I, Van Nieuwenhuysen E, Achimas-Cadariu P, Glajzer J, Woopen H, Wienert S, Taube ET, Stanske M, Kulbe H, Denkert C, Sehouli J, Braicu EI.

Histopathology. 2018 Dec;73(6):1002-1012. doi: 10.1111/his.13711. Epub 2018 Oct 7.

PMID:
30007074
6.

Palbociclib in highly pretreated metastatic ER-positive HER2-negative breast cancer.

Hoste G, Punie K, Wildiers H, Beuselinck B, Lefever I, Van Nieuwenhuysen E, Han SN, Berteloot P, Concin N, Salihi R, Vergote I, Neven P.

Breast Cancer Res Treat. 2018 May 16. doi: 10.1007/s10549-018-4827-6. [Epub ahead of print]

PMID:
29766363
7.

AB0 blood groups and rhesus factor expression as prognostic parameters in patients with epithelial ovarian cancer - a retrospective multi-centre study.

Seebacher V, Polterauer S, Reinthaller A, Koelbl H, Achleitner R, Berger A, Concin N.

BMC Cancer. 2018 Apr 19;18(1):447. doi: 10.1186/s12885-018-4289-6.

8.

Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients- A study of the OVCAD consortium.

Gostner JM, Obermayr E, Braicu IE, Concin N, Mahner S, Vanderstichele A, Sehouli J, Vergote I, Fuchs D, Zeillinger R.

Gynecol Oncol. 2018 May;149(2):371-380. doi: 10.1016/j.ygyno.2018.02.020. Epub 2018 Mar 9.

PMID:
29530331
9.

The relative risk of second primary cancers in Austria's western states: a retrospective cohort study.

Preyer O, Concin N, Obermair A, Concin H, Ulmer H, Oberaigner W.

BMC Cancer. 2017 Oct 24;17(1):699. doi: 10.1186/s12885-017-3683-9.

10.

Use of Underarm Cosmetic Products in Relation to Risk of Breast Cancer: A Case-Control Study.

Linhart C, Talasz H, Morandi EM, Exley C, Lindner HH, Taucher S, Egle D, Hubalek M, Concin N, Ulmer H.

EBioMedicine. 2017 Jul;21:79-85. doi: 10.1016/j.ebiom.2017.06.005. Epub 2017 Jun 6.

11.

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.

Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi T.

Cancer Res. 2017 Mar 15;77(6):1250-1260. doi: 10.1158/0008-5472.CAN-16-2179. Review.

12.

The Impact of the Duration of Adjuvant Chemotherapy on Survival in Patients with Epithelial Ovarian Cancer - A Retrospective Study.

Seebacher V, Reinthaller A, Koelbl H, Concin N, Nehoda R, Polterauer S.

PLoS One. 2017 Jan 6;12(1):e0169272. doi: 10.1371/journal.pone.0169272. eCollection 2017.

13.

L1CAM in the Early Enteric and Urogenital System.

Pechriggl EJ, Concin N, Blumer MJ, Bitsche M, Zwierzina M, Dudas J, Koziel K, Altevogt P, Zeimet AG, Fritsch H.

J Histochem Cytochem. 2017 Jan;65(1):21-32. doi: 10.1369/0022155416677241. Epub 2016 Nov 12.

14.

Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells.

Kramer D, Stark N, Schulz-Heddergott R, Erytch N, Edmunds S, Roßmann L, Bastians H, Concin N, Moll UM, Dobbelstein M.

Cell Death Differ. 2017 Feb;24(2):300-316. doi: 10.1038/cdd.2016.124. Epub 2016 Nov 11. Erratum in: Cell Death Differ. 2018 Sep 3;:.

15.

Role of IGF-I in Primary Ovarian Cancer - A Study of the OVCAD European Consortium.

Rohr I, Zeillinger R, Heinrich M, Concin N, Vergote I, Nassir M, Mahner S, VAN Nieuwenhuysen E, Trillsch F, Cacsire-Tong D, Chekerov R, Sehouli J, Braicu EI.

Anticancer Res. 2016 Mar;36(3):1015-22.

PMID:
26976992
16.

Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer.

Schmid G, Notaro S, Reimer D, Abdel-Azim S, Duggan-Peer M, Holly J, Fiegl H, Rössler J, Wiedemair A, Concin N, Altevogt P, Marth C, Zeimet AG.

BMC Cancer. 2016 Feb 15;16:102. doi: 10.1186/s12885-016-2135-2.

17.

γ-Glutamyltransferase and Breast Cancer Risk Beyond Alcohol Consumption and Other Life Style Factors - A Pooled Cohort Analysis.

Preyer O, Johansen D, Holly J, Stocks T, Pompella A, Nagel G, Concin H, Ulmer H, Concin N.

PLoS One. 2016 Feb 10;11(2):e0149122. doi: 10.1371/journal.pone.0149122. eCollection 2016.

18.

The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study.

Nassir M, Guan J, Luketina H, Siepmann T, Rohr I, Richter R, Castillo-Tong DC, Zeillinger R, Vergote I, Van Nieuwenhuysen E, Concin N, Marth C, Hall C, Mahner S, Woelber L, Sehouli J, Braicu EI.

Tumour Biol. 2016 Mar;37(3):3009-16. doi: 10.1007/s13277-015-4031-9. Epub 2015 Sep 29.

PMID:
26419591
19.

Jump in the fire--heat shock proteins and their impact on ovarian cancer therapy.

Stope MB, Koensgen D, Burchardt M, Concin N, Zygmunt M, Mustea A.

Crit Rev Oncol Hematol. 2016 Jan;97:152-6. doi: 10.1016/j.critrevonc.2015.08.008. Epub 2015 Aug 13. Review.

PMID:
26318096
20.

Prognostic relevance of pretherapeutic gamma-glutamyltransferase in patients with primary metastatic breast cancer.

Staudigl C, Concin N, Grimm C, Pfeiler G, Nehoda R, Singer CF, Polterauer S.

PLoS One. 2015 Apr 27;10(4):e0125317. doi: 10.1371/journal.pone.0125317. eCollection 2015.

21.

HIF1α is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer - a study of the OVCAD Consortium.

Braicu EI, Luketina H, Richter R, Cacsire Castillo-Tong D, Lambrechts S, Mahner S, Concin N, Mentze M, Zeillinger R, Vergote I, Sehouli J.

Onco Targets Ther. 2014 Sep 11;7:1563-9. doi: 10.2147/OTT.S65373. eCollection 2014.

22.

Mineral oil in human tissues, part II: characterization of the accumulated hydrocarbons by comprehensive two-dimensional gas chromatography.

Biedermann M, Barp L, Kornauth C, Würger T, Rudas M, Reiner A, Concin N, Grob K.

Sci Total Environ. 2015 Feb 15;506-507:644-55. doi: 10.1016/j.scitotenv.2014.07.038. Epub 2014 Jul 23.

PMID:
25063713
23.

BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).

Ruscito I, Dimitrova D, Vasconcelos I, Gellhaus K, Schwachula T, Bellati F, Zeillinger R, Benedetti-Panici P, Vergote I, Mahner S, Cacsire-Tong D, Concin N, Darb-Esfahani S, Lambrechts S, Sehouli J, Olek S, Braicu EI.

Eur J Cancer. 2014 Aug;50(12):2090-8. doi: 10.1016/j.ejca.2014.05.001. Epub 2014 Jun 2.

PMID:
24889916
24.

Mineral oil in human tissues, Part I: concentrations and molecular mass distributions.

Barp L, Kornauth C, Wuerger T, Rudas M, Biedermann M, Reiner A, Concin N, Grob K.

Food Chem Toxicol. 2014 Oct;72:312-21. doi: 10.1016/j.fct.2014.04.029. Epub 2014 Apr 26.

PMID:
24780493
25.

Suppression of acetylpolyamine oxidase by selected AP-1 members regulates DNp73 abundance: mechanistic insights for overcoming DNp73-mediated resistance to chemotherapeutic drugs.

Bunjobpol W, Dulloo I, Igarashi K, Concin N, Matsuo K, Sabapathy K.

Cell Death Differ. 2014 Aug;21(8):1240-9. doi: 10.1038/cdd.2014.41. Epub 2014 Apr 11.

26.

Association of gamma-glutamyltransferase with severity of disease at diagnosis and prognosis of ovarian cancer.

Grimm C, Hofstetter G, Aust S, Mutz-Dehbalaie I, Bruch M, Heinze G, Rahhal-Schupp J, Reinthaller A, Concin N, Polterauer S.

Br J Cancer. 2013 Aug 6;109(3):610-4. doi: 10.1038/bjc.2013.323. Epub 2013 Jul 16.

27.

The time interval from surgery to start of chemotherapy significantly impacts prognosis in patients with advanced serous ovarian carcinoma - analysis of patient data in the prospective OVCAD study.

Hofstetter G, Concin N, Braicu I, Chekerov R, Sehouli J, Cadron I, Van Gorp T, Trillsch F, Mahner S, Ulmer H, Grimm C, Castillo-Tong DC, Zeillinger R, Zeimet AG, Vergote I.

Gynecol Oncol. 2013 Oct;131(1):15-20. doi: 10.1016/j.ygyno.2013.07.086. Epub 2013 Jul 20.

PMID:
23877013
28.

Treatment reality in elderly patients with advanced ovarian cancer: a prospective analysis of the OVCAD consortium.

Trillsch F, Woelber L, Eulenburg C, Braicu I, Lambrechts S, Chekerov R, van Nieuwenhuysen E, Speiser P, Zeimet A, Castillo-Tong DC, Concin N, Zeillinger R, Vergote I, Mahner S, Sehouli J.

J Ovarian Res. 2013 Jun 28;6(1):42. doi: 10.1186/1757-2215-6-42.

29.

Does thyroid-stimulating hormone influence the prognosis of patients with endometrial cancer? A multicentre trial.

Seebacher V, Hofstetter G, Polterauer S, Reinthaller A, Grimm C, Schwameis R, Taucher S, Wagener A, Marth C, Concin N.

Br J Cancer. 2013 Jul 9;109(1):215-8. doi: 10.1038/bjc.2013.282. Epub 2013 Jun 13.

30.

A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium.

Pils D, Tong D, Hager G, Obermayr E, Aust S, Heinze G, Kohl M, Schuster E, Wolf A, Sehouli J, Braicu I, Vergote I, Van Gorp T, Mahner S, Concin N, Speiser P, Zeillinger R.

BMC Cancer. 2013 Apr 3;13:178. doi: 10.1186/1471-2407-13-178.

31.

Lifestyle-related biomarkers and endometrial cancer survival: elevated gamma-glutamyltransferase as an important risk factor.

Edlinger M, Concin N, Concin H, Nagel G, Ulmer H, Göbel G.

Cancer Epidemiol. 2013 Apr;37(2):156-61. doi: 10.1016/j.canep.2012.12.003. Epub 2013 Jan 5.

PMID:
23295001
32.

Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study.

Braicu EI, Fotopoulou C, Van Gorp T, Richter R, Chekerov R, Hall C, Butz H, Castillo-Tong DC, Mahner S, Zeillinger R, Concin N, Vergote I, Sehouli J.

Gynecol Oncol. 2013 Feb;128(2):245-51. doi: 10.1016/j.ygyno.2012.11.023. Epub 2012 Nov 21.

PMID:
23178313
33.

Does duration of hysteroscopy increase the risk of disease recurrence in patients with endometrial cancer? A multi-centre trial.

Tempfer C, Froese G, Buerkle B, Polterauer S, Grimm C, Concin N, Hofstetter G, Weigert M, Oehler MK.

Exp Ther Med. 2011 Sep;2(5):991-995. Epub 2011 Jun 30.

34.

Nomogram prediction for overall survival of patients diagnosed with cervical cancer.

Polterauer S, Grimm C, Hofstetter G, Concin N, Natter C, Sturdza A, Pötter R, Marth C, Reinthaller A, Heinze G.

Br J Cancer. 2012 Sep 4;107(6):918-24. doi: 10.1038/bjc.2012.340. Epub 2012 Aug 7.

35.

Ovarian cancer stem cells.

Zeimet AG, Reimer D, Sopper S, Boesch M, Martowicz A, Roessler J, Wiedemair AM, Rumpold H, Untergasser G, Concin N, Hofstetter G, Muller-Holzner E, Fiegl H, Marth C, Wolf D, Pesta M, Hatina J.

Neoplasma. 2012;59(6):747-55. doi: 10.4149/neo_2012_094. Review.

PMID:
22862176
36.

Prognostic value of lymph node ratio and clinicopathologic parameters in patients diagnosed with stage IIIC endometrial cancer.

Polterauer S, Khalil S, Zivanovic O, Abu-Rustum NR, Hofstetter G, Concin N, Grimm C, Reinthaller A, Barakat RR, Leitao MM Jr.

Obstet Gynecol. 2012 Jun;119(6):1210-8. doi: 10.1097/AOG.0b013e318255060c.

PMID:
22617586
37.

External validation of a nomogram predicting overall survival of patients diagnosed with endometrial cancer.

Polterauer S, Zhou Q, Grimm C, Seebacher V, Reinthaller A, Hofstetter G, Concin N, Leitao MM Jr, Barakat RR, Abu-Rustum NR, Iasonos A.

Gynecol Oncol. 2012 Jun;125(3):526-30. doi: 10.1016/j.ygyno.2012.03.030. Epub 2012 Mar 23.

38.

Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system.

Seeber B, Ziehr SC, Gschlieβer A, Moser C, Mattle V, Seger C, Griesmacher A, Concin N, Concin H, Wildt L.

Contraception. 2012 Oct;86(4):345-9. doi: 10.1016/j.contraception.2012.01.015. Epub 2012 Mar 6. Erratum in: Contraception. 2013 Jul;88(1):194. Gschliesser, Aandrea [corrected to Gschlieβer, Andreas].

PMID:
22402256
39.

Prognostic significance of gamma-glutamyltransferase in patients with endometrial cancer: a multi-centre trial.

Seebacher V, Polterauer S, Grimm C, Rahhal J, Hofstetter G, Bauer EM, Husslein H, Leipold H, Marth C, Reinthaller A, Concin N.

Br J Cancer. 2012 Apr 24;106(9):1551-5. doi: 10.1038/bjc.2012.16. Epub 2012 Feb 7.

40.

Prognostic value of residual tumor size in patients with epithelial ovarian cancer FIGO stages IIA-IV: analysis of the OVCAD data.

Polterauer S, Vergote I, Concin N, Braicu I, Chekerov R, Mahner S, Woelber L, Cadron I, Van Gorp T, Zeillinger R, Castillo-Tong DC, Sehouli J.

Int J Gynecol Cancer. 2012 Mar;22(3):380-5. doi: 10.1097/IGC.0b013e31823de6ae.

PMID:
22266934
41.

The N-terminally truncated p53 isoform Δ40p53 influences prognosis in mucinous ovarian cancer.

Hofstetter G, Berger A, Berger R, Zorić A, Braicu EI, Reimer D, Fiegl H, Marth C, Zeimet AG, Ulmer H, Moll U, Zeillinger R, Concin N.

Int J Gynecol Cancer. 2012 Mar;22(3):372-9. doi: 10.1097/IGC.0b013e31823ca031.

PMID:
22246403
42.

MDM2 SNP309 modifies the prognostic significance of the p53 mutational status in patients with ovarian cancer.

Hofstetter G, Berger A, Bauer EM, Schuster E, Wolf A, Chamson M, Müller-Holzner E, Reimer D, Braicu EI, Sehouli J, Ulmer H, Cacsire Castillo-Tong D, Zeillinger R, Concin N.

Oncol Rep. 2012 Mar;27(3):673-7. doi: 10.3892/or.2011.1560. Epub 2011 Nov 23.

PMID:
22134502
43.

Δ133p53 is an independent prognostic marker in p53 mutant advanced serous ovarian cancer.

Hofstetter G, Berger A, Schuster E, Wolf A, Hager G, Vergote I, Cadron I, Sehouli J, Braicu EI, Mahner S, Speiser P, Marth C, Zeimet AG, Ulmer H, Zeillinger R, Concin N.

Br J Cancer. 2011 Nov 8;105(10):1593-9. doi: 10.1038/bjc.2011.433. Epub 2011 Oct 18.

44.

Clinical relevance of TAp73 and ΔNp73 protein expression in ovarian cancer: a series of 83 cases and review of the literature.

Hofstetter G, Berger A, Chamson M, Müller-Holzner E, Reimer D, Ulmer H, Uramoto H, Marth C, Zeimet AG, Zeillinger R, Concin N.

Int J Gynecol Pathol. 2011 Nov;30(6):527-31. doi: 10.1097/PGP.0b013e31821ac519. Review. Erratum in: Int J Gynecol Pathol. 2012 May;31(3):296. G Zeimet, A [corrected to Zeimet, Alain G]. Int J Gynecol Pathol. 2012 Mar;31(2):191. Zeimet, Alain G [corrected to G Zeimet, A].

PMID:
21979586
45.

Evidence for cosmetics as a source of mineral oil contamination in women.

Concin N, Hofstetter G, Plattner B, Tomovski C, Fiselier K, Gerritzen K, Semsroth S, Zeimet AG, Marth C, Siegl H, Rieger K, Ulmer H, Concin H, Grob K.

J Womens Health (Larchmt). 2011 Nov;20(11):1713-9. doi: 10.1089/jwh.2011.2829. Epub 2011 Oct 4.

PMID:
21970597
46.

Relevance of gamma-glutamyltransferase--a marker for apoptotic balance--in predicting tumor stage and prognosis in cervical cancer.

Polterauer S, Hofstetter G, Grimm C, Rahhal J, Mailath-Pokorny M, Kohl M, Concin N, Tempfer C, Marth C, Reinthaller A.

Gynecol Oncol. 2011 Sep;122(3):590-4. doi: 10.1016/j.ygyno.2011.05.027. Epub 2011 Jun 12.

PMID:
21664662
47.

Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer.

Reimer D, Hubalek M, Kiefel H, Riedle S, Skvortsov S, Erdel M, Hofstetter G, Concin N, Fiegl H, Müller-Holzner E, Marth C, Altevogt P, Zeimet AG.

Oncogene. 2011 Sep 22;30(38):4038-49. doi: 10.1038/onc.2011.119. Epub 2011 Apr 25.

PMID:
21516127
48.

Gene expression of PMP22 is an independent prognostic factor for disease-free and overall survival in breast cancer patients.

Tong D, Heinze G, Pils D, Wolf A, Singer CF, Concin N, Hofstetter G, Schiebel I, Rudas M, Zeillinger R.

BMC Cancer. 2010 Dec 15;10:682. doi: 10.1186/1471-2407-10-682.

49.

Urinary neopterin does not reflect the local antitumor immune milieu in ovarian cancer.

Zeimet AG, Reimer D, Schwentner L, Fuchs D, Wolf D, Fuith LC, Fiegl H, Doppler W, Concin N, Daxenbichler G, Marth C.

Cancer Immunol Immunother. 2010 Dec;59(12):1813-23. doi: 10.1007/s00262-010-0907-0. Epub 2010 Aug 18.

PMID:
20717669
50.

E2F3a is critically involved in epidermal growth factor receptor-directed proliferation in ovarian cancer.

Reimer D, Hubalek M, Riedle S, Skvortsov S, Erdel M, Concin N, Fiegl H, Müller-Holzner E, Marth C, Illmensee K, Altevogt P, Zeimet AG.

Cancer Res. 2010 Jun 1;70(11):4613-23. doi: 10.1158/0008-5472.CAN-09-3551. Epub 2010 May 11.

Supplemental Content

Loading ...
Support Center